Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $60.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at ($2.68) EPS.

Several other research firms have also commented on ARWR. Morgan Stanley lowered their target price on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an equal weight rating for the company in a report on Monday, May 13th. Cantor Fitzgerald reiterated an overweight rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. Chardan Capital restated a buy rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. The Goldman Sachs Group began coverage on shares of Arrowhead Pharmaceuticals in a report on Wednesday, June 5th. They issued a neutral rating and a $31.00 price objective on the stock. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a sell rating in a research note on Tuesday, July 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $43.25.

Arrowhead Pharmaceuticals Trading Up 0.1 %

Shares of NASDAQ:ARWR opened at $28.94 on Tuesday. The firm has a market cap of $3.59 billion, a PE ratio of -6.81 and a beta of 0.94. The company has a fifty day simple moving average of $25.80 and a 200 day simple moving average of $27.97. Arrowhead Pharmaceuticals has a 12-month low of $20.67 and a 12-month high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same period last year, the company earned $0.45 earnings per share. The firm’s revenue for the quarter was down 100.0% on a year-over-year basis. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.04 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider Tracie Oliver sold 9,394 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total transaction of $237,480.32. Following the transaction, the insider now owns 127,107 shares in the company, valued at $3,213,264.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the transaction, the director now owns 30,205 shares in the company, valued at approximately $704,078.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the sale, the insider now owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp grew its position in Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 354 shares during the period. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 22.9% during the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 447 shares in the last quarter. Washington Trust Advisors Inc. bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $25,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Arrowhead Pharmaceuticals by 12.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 952 shares in the last quarter. Finally, Securian Asset Management Inc. grew its stake in Arrowhead Pharmaceuticals by 12.5% during the first quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock worth $289,000 after buying an additional 1,121 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.